{"id":"W2999581422","doi":"10.1016/s0923-7534(20)34201-0","title":"Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Docetaxel; Trastuzumab; Metastatic breast cancer; Bevacizumab; Oncology; Internal medicine; HER2 negative; Breast cancer; Phases of clinical research; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002161406,0.00076878,0.001138145,0.0002604634,0.0002775971,0.0008701493,0.0005130226,0.0009682651,0.005463872],"category_scores_gemma":[0.002062274,0.000252966,0.0007229173,0.000299941,0.0003369459,0.0007577314,0.0004133023,0.001770239,0.00154159],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007046638,"about_ca_system_score_gemma":0.001004216,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009843793,"about_ca_topic_score_gemma":0.003728697,"domain_scores_codex":[0.9994361,0.0003398485,0.00001633744,0.00006649765,0.0000541538,0.00008699429],"domain_scores_gemma":[0.9993325,0.0001411008,0.0001238268,0.00004802803,0.00005158546,0.0003030025],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5542651,0.01025815,0.008896512,0.001002033,0.002753626,0.0002307379,0.0001724647,0.003716524,0.01881006,0.001401121,0.05672751,0.3417661],"study_design_scores_gemma":[0.6412076,0.1877003,0.07848702,0.0002885193,0.004174375,0.0007874214,0.0001475633,0.003195261,0.008656899,0.004575756,0.07067103,0.0001082319],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9291426,0.01613275,0.002057155,0.008789229,0.001171922,0.002001568,0.01975593,0.000610251,0.02033853],"genre_scores_gemma":[0.9374774,0.004311252,0.00571205,0.008514685,0.0006822832,0.001646215,0.02508288,0.0001348514,0.01643856],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005463872,"threshold_uncertainty_score":0.01827848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.22965652475487,"score_gpt":0.5029663557028642,"score_spread":0.2733098309479942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}